Oekolp-Creme (Estriol)

Estriol, the active ingredient in Oekolp-Creme, is an estrogen presented as a topical cream for dermal use. It is used to treat estrogen‑deficient skin conditions in post‑menopausal women. GNH USA supplies Oekolp-Creme as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and clinics worldwide.

GNH USA supplies Oekolp-Creme as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and clinics worldwide.

Oekolp-Creme contains estriol, an estrogen that acts on the skin’s estrogen‑dependent pathways. It is indicated for: - Atrophic vaginitis: improves mucosal integrity and reduces dryness. - Genitourinary syndrome of menopause (GSM): alleviates irritation, burning and dyspareunia. - Post‑menopausal vulvovaginal atrophy: restores tissue elasticity and hydration. - Estrogen‑deficient dermatoses: supports skin barrier function and reduces erythema.

Estriol cream is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Local itching or mild burning sensation. - Redness or mild erythema at the application site. - Slight swelling or edema of the skin. - Dryness or flaking of the treated area.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis) with swelling of the face or throat. - Contact dermatitis with intense itching, blistering or rash. - Unexplained vaginal bleeding. - Hormone‑sensitive tumor progression.

When using Oekolp-Creme, consider the following precautions: - Contraindication: Do not use in patients with known estrogen‑dependent malignancies. - Pregnancy: Avoid use during pregnancy unless specifically prescribed. - Breastfeeding: Use with caution; limited data are available. - Drug interactions: Review concomitant estrogen‑containing products. - Monitoring: Periodic assessment of symptom improvement and skin condition is recommended. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Estradiol‑type compounds can interact with several drug classes.

Major Interactions (Avoid): - Combined hormonal contraceptives: increased risk of thromboembolic events. - Systemic estrogen therapy: additive estrogenic effects may lead to hormonal imbalance.

Moderate Interactions (Monitor Closely): - Antifungal azoles (e.g., ketoconazole): may alter estriol metabolism. - Anticoagulants (e.g., warfarin): estrogen can affect coagulation parameters. - Thyroid hormone replacement: estrogen may increase thyroid‑binding globulin, altering dosage needs. - Selective estrogen receptor modulators (SERMs): may antagonize topical estriol effects.